The DOI matches its Crossref record; 184 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessAbstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup, 2013, Candida and Candidaemia: Susceptibility and Epidemiology, Dan. Med. J.
- Disputedcites [43] Hii, 2015, Changing epidemiology of candidemia in a medical center in middle Taiwan, J. Microbiol. Immunol. Infect. sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Farahat, 2014, Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia, Int. J. Infect. Dis. source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning, D.W. (2016). Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized. Philos. Trans. R. Soc. B, 371. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao, 2014, Prevalence of infectious keratitis in Central China, BMC Ophthalmol. source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning, 2017, Calling upon all public health mycologists, Eur. J. Clin. Microbiol. Infect. Dis. sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown, 2012, Hidden Killers: Human Fungal Infections, Sci. Transl. Med. source
- Partly supportedcites [2] Denning, D.W. (2016). Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized. Philos. Trans. R. Soc. B, 371. sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Meintjes, 2014, A neglected epidemic: Fungal infections in HIV/AIDS, Trends Microbiol. source
- Not checked — no full text of the sourcecites [4] Guinea, 2010, Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome, Clin. Microbiol. Infect. source
- Not checked — no full text of the sourcecites [5] Marr, 2002, Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors, Blood source
- Not checked — no full text of the sourcecites [6] Limper, A.H., Adenis, A., Le, T., and Harrison, T.S. (2017). Fungal infections in HIV/AIDS. Lancet Infect. Dis. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning, 2013, Global fungal Burden, Mycoses, 56, 13
- The Fungal Infection Trust (2011, January 18). How common are fungal diseases?. Proceedings of the Fungal Research Trust 20th Anniversary Meeting, London, UK. Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf.
- Jayasekera, 2013, The burden of serious fungal infections in Sri Lanka, Mycoses, 56, 103
- Gugnani, 2017, Burden of serious fungal infections in Bangladesh, Eur. J. Clin. Microbiol. Infect. Dis., 36, 965, 10.1007/s10096-017-2921-z · DOI · Paper page
- Samayoa, B., Isern, V., Serra, L., Rivera, B.E., Nikiforov, M., Arathoon, E., Samayoa, C., Vallès, X., Prieto, L., and Álvarez, C. (2010, January 18–23). Preliminary results of a prospective cohort of HIV+ patients in Guatemala. Proceedings of the XVIII International AIDS Conference, Vienna, Austria.
- Gopinathan, 2002, The Epidemiological Features and Laboratory Results of Fungal Keratitis, Eye, 21, 555
Cited by
Items 1,401–1,500 of 2,931
Increased prevalence of fungemia in Medina, Saudi Arabia
Khateb, A. M., Alofi, F. S., & Almutairi, A. Z. (2023) · Frontiers in Epidemiology · doi:10.3389/fepid.2023.1180331 · Cited by 8
Maione, A., Buonanno, A., Galdiero, M., de Alteriis, E., Petrillo, F., Reibaldi, M., Guida, M., & Galdiero, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612876 · Cited by 8
“Bacterial/fungal biofilms, namely polymicrobial communities, are considered one of the leading conditions predisposing to invasive human infections also related to hospitalization of clinical complexity and to many co-morbidities, such as cancer, chronic diseases, neutropenia, transplants, and mucositis [32].”
BackgroundDas, S., Capoor, M. R., Singh, A., & Agarwal, Y. (2023) · Mycopathologia · doi:10.1007/s11046-023-00798-y · Cited by 8
“IA accounts for more than 80% of invasive fungal diseases (IFD), and along with invasive candidiasis (IC) the burden is more than 95% of all IFD in all risk groups [1–4] Worldwide estimates reveal that over 1.8 million cases of IFDs occurred in 2017, out of which around 250,000 cases were IA [5, 6].”
BackgroundInfluentialRollin‐Pinheiro, R., de Moraes, D., Bayona-Pacheco, B. L., Curvelo, J. A. D. R., dos Santos, G. M. P., Xisto, M. I. D. D. S., Borba-Santos, L. P., Rozental, S., Ferreira‐Pereira, A., & Barreto‐Bergter, E. (2023) · Journal of Fungi · doi:10.3390/jof9111115 · Cited by 8
“In healthcare environments, Candida infections are the most common fungal disease associated with nosocomial acquired infections [4].”
BackgroundKovács, R., Majoros, L., Stemler, J., Cornely, O. A., & Salmanton‐García, J. (2023) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361231219315 · Cited by 7
Belizário, J. A., Bila, N. M., Vaso, C. O., et al. (2024) · Microorganisms · doi:10.3390/microorganisms12010191 · Cited by 7
New Breath Diagnostics for Fungal Disease
Diefenderfer, J., Bean, H. D., & Keppler, E. A. H. (2024) · Current Clinical Microbiology Reports · doi:10.1007/s40588-024-00216-x · Cited by 9
Cao, Y., Li, Y., Wang, M., Wang, L., Fang, Y., Wu, Y., Liu, Y., Liu, Y., Hao, Z., Kang, H., et al. (2024) · Shock · doi:10.1097/shk.0000000000002312 · Cited by 8
“Fungal infections contribute to approximately 1.6 million deaths annually and impose a significant economic burden on patients and society (7).”
BackgroundInfluentialItraconazole in human medicine and veterinary practice
Sousa, Y. V., Santiago, M. G., de Souza, B. M., Keller, K. M., de Oliveira, C. S. F., Mendoza, L., Vilela, R. V., & Goulart, G. A. C. (2024) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2024.101473 · Cited by 7
Yu, S., He, Y., Liu, Y., Ji, S., Wang, Y., & Sun, B. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00710 · Cited by 9
Therapeutic Drug Monitoring and Biomarkers; towards Better Dosing of Antimicrobial Therapy
Wehbe, E., Patanwala, A. E., Lu, C. Y., Kim, H. Y., STOCKER, S. L., & Alffenaar, J. C. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16050677 · Cited by 7
“Aspergillus , an opportunistic fungal species, is the most common cause of invasive mould infections in immunocompromised and critically ill patients [8–10].”
BackgroundViale, P., Mirandola, S., Natalini, C., Esposti, L. D., Dovizio, M., Veronesi, C., Forcina, G., Navalesi, P., & Boscolo, A. (2024) · Mycoses · doi:10.1111/myc.13779 · Cited by 7
Chromoblastomycosis in Brazil: A review of 450 published cases
BARBOSA, L. S. D. P., de Souza, Y. R. C., Sasaki, C. S., Santos, D. W. D. C. L., & Rossato, L. L. (2024) · Revista da Sociedade Brasileira de Medicina Tropical · doi:10.1590/0037-8682-0132-2024 · Cited by 7
“The estimated global burden of CBM is 10,000 cases annually, highlighting the importance of understanding the evolution of the disease 62 .”
Amin, H., Kantroo, H. A., Mubarak, M. M., Bhat, S. A., Ahmad, Z., & Bhat, K. A. (2024) · RSC Advances · doi:10.1039/d4ra05020g · Cited by 9
The Potential Antifungal Activity of the Developed Palladium Nanoparticles
Bi, S., Srivastava, R., & Ahmed, T. (2024) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/3053 · Cited by 8
Molaeitabari, A., & Dahms, T. E. S. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02754-24 · Cited by 10
Pllana-Hajdari, D., Cogliati, M., Čičmak, L., et al. (2019) · Journal of Fungi · doi:10.3390/jof5040099 · Cited by 7
“An estimated 220,000 cases of cryptococcal meningitis complicate HIV/AIDS worldwide each year, resulting in nearly 181,000 deaths annually [3,4].”
Backgroundda Silva, L. C., Oliveira, L. V. N., Silva, F. B., et al. (2019) · Mycoses · doi:10.1111/myc.13036 · Cited by 7
“24 (1) %Relative frequency ofHM/year= average annual number ofHM”
BackgroundMethodInfluentialMontalvo, R., Pomalaza, G., Sandoval, M., et al. (2020) · Mycopathologia · doi:10.1007/s11046-020-00437-w · Cited by 7
“Histoplasmosis is an opportunistic fungal infection caused by Histoplasma capsulatum; a worldwide level is estimated annually 100,000 cases of disseminated histoplasmosis [1].”
BackgroundA Low‐Cost Tebuconazole‐Based Screening Test for Azole‐Resistant Aspergillus fumigatus
Brackin, A. P., Shelton, J., Abdolrasouli, A., Fisher, M. C., & Sewell, T. R. (2020) · Current Protocols in Microbiology · doi:10.1002/cpmc.112 · Cited by 5
Microbial siderophores: Markers of infectious diseases
Dobiáš, R., & Havlíček, V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820084-1.00002-8 · Cited by 7
Cross-Disciplinary Genomics Approaches to Studying Emerging Fungal Infections
Ghosh, P. N., Brookes, L. M., Edwards, H. M., Fisher, M. C., Jervis, P., Kappel, D., Sewell, T. R., Shelton, J., Skelly, E., & Rhodes, J. L. (2020) · Life · doi:10.3390/life10120315 · Cited by 6
“pathogens is challenging due to a lack of research investment and prioritisation [1,4].”
BackgroundFilamentous Fungal Infections in a Tertiary Care Setting: Epidemiology and Clinical Outcome
den Nest, M. V., Wagner, G., Riesenhuber, M., et al. (2021) · Journal of Fungi · doi:10.3390/jof7010040 · Cited by 7
“The incidence rates for invasive aspergillosis are roughly estimated at 4.1 per 100,000 per year for Austria [11].”
BackgroundInfluentialPéret, V. A. C., Reis, A. C. C., Silva, N. C., et al. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.130186 · Cited by 7
ISMAIL, F., Ghani, A., & Akbar, S. (2021) · RADS Journal of Biological Research & Applied Sciences · doi:10.37962/jbas.v12i1.348 · Cited by 8
Moloney, N. M., Larkin, A., Xu, L., Fitzpatrick, D. A., Crean, H. L., Walshe, K., Haas, H., Decristoforo, C., & Doyle, S. (2021) · Analytical Biochemistry · doi:10.1016/j.ab.2021.114384 · Cited by 7
Microbial Pathogenesis: Mechanism and Recent Updates on Microbial Diversity of Pathogens
Dhagat, S., & Eswari, S. (2022) · Springer eBooks · doi:10.1007/978-981-16-3120-7_3 · Cited by 8
Yashunsky, D. V., Dorokhova, V. S., Сергеевна, К. Б., Paulovičová, E., Krylov, V. B., & Nifantiev, N. E. (2021) · Russian Chemical Bulletin · doi:10.1007/s11172-021-3334-9 · Cited by 7
Clinical and microbiological analysis of fungal keratitis in Toronto, Canada: A 20-year study
Trinh, T., Emami, S., Gould, J., Mimouni, M., Cohen, E., Rootman, D. S., Slomovic, A. R., & Chan, C. C. (2022) · Medical Mycology · doi:10.1093/mmy/myac047 · Cited by 7
Bioactive Antimicrobial Peptides: A New Weapon to Counteract Zoonosis
Zupin, L., dos Santos-Silva, C. A., Mughrbi, A. R. H. A., Vilela, L. M. B., Benko‐Iseppon, A. M., & Crovella, S. (2022) · Microorganisms · doi:10.3390/microorganisms10081591 · Cited by 7
“Data from the Leading International Fungal Education (LIFE) website in 2017 (updated in 2018) estimate around 223,100 annual cases of cryptococcal meningitis in the immunocompromised, with a mortality rate of 10% and greater than 70% in the US and Africa, respectively, leading to approximately 181,000 deaths per year…”
BackgroundNanocosmeceuticals: Concept, opportunities, and challenges
Das, S., Das, S., & Das, M. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91077-4.00008-9 · Cited by 9
Valladales‐Restrepo, L. F., Ospina-Cano, J. A., Aristizábal-Carmona, B. S., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11121805 · Cited by 7
“which have a significant impact on their lives and are sometimes fatal [2].”
BackgroundDhawale, S. A., Pandit, M., Thete, K., Ighe, D., Gawale, S., Bhosle, P., & Lokwani, D. K. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2164797 · Cited by 7
“They are responsible for a number of contagious infections, including ringworm, muscle head tingling, athlete’s foot ony-chomycosis and contagious nail diseases (Bongomin et al., 2017; Bow et al., 1997).”
BackgroundCavassin, F. B., Vidal, J. E., Baú-Carneiro, J. L., et al. (2023) · Medical Mycology · doi:10.1093/mmy/myad011 · Cited by 7
Filamentous Fungi Infections: Yet Another Victim of COVID-19?
Cighir, A., Mare, A. D., Cighir, T., Coșeriu, R. L., Vintilă, C., & Man, A. (2023) · Life · doi:10.3390/life13020546 · Cited by 9
“published a study on the global incidence of different mycoses and their impact on human health [11].”
Vicente, P. V., Parra-Fariñas, R., Alonso‐Sardón, M., Benéitez-Andrés, E., Rodríguez-Alonso, B., Romero‐Alegría, Á., Almeida, H., Muro, A., Pardo‐Lledías, J., & Belhassen‐García, M. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.03.022 · Cited by 7
Zhang, M., Wang, M.-Y., Yu, Y., Meng, S.-S., Yan, C.-W., Zhiyong, W., & Li, Y. (2023) · CrystEngComm · doi:10.1039/d3ce00082f · Cited by 7
Invasive Fungal Infections: The Early Killer after Liver Transplantation
Breitkopf, R., Treml, B., Bukumirić, Z., Innerhofer, N., Fodor, M., & Rajšić, S. (2023) · Journal of Fungi · doi:10.3390/jof9060655 · Cited by 8
“This is of particular importance since invasive fungal diseases are increasing globally [55].”
BackgroundFungal Diseases of the Hair and Scalp
Trüeb, R. M., & Dias, M. F. R. G. (2023) · Springer eBooks · doi:10.1007/978-3-031-30754-6_5 · Cited by 13
Nanotherapeutics for the Delivery of Antifungal Drugs
Aderibigbe, B. A. (2024) · Therapeutic Delivery · doi:10.4155/tde-2023-0090 · Cited by 12
Brakel, A., Grochow, T., Fritsche, S., Knappe, D., Krizsan, A., Fietz, S. A., Alber, G., Hoffmann, R., & Müller, U. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1328890 · Cited by 9
Prevalence, Causes, and Management Strategies of Fungal Diseases in Northern Regions of Bangladesh
Akanda, M. K. M., Sultana, R., Rana, M. M., Hossain, M. A., Barik, S. M. A., Islam, M. R., Islam, M. N., & Parvez, G. M. (2024) · Sciences of Pharmacy · doi:10.58920/sciphar0301191 · Cited by 12
Human–Fungal Pathogen Interactions from the Perspective of Immunoproteomics Analyses
Wangsanut, T., & Pongpom, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063531 · Cited by 7
“Indeed, the global burden of fungal diseases is estimated to be over 5.7 billion [1].”
BackgroundInfluentialDonati, L., Pierantoni, D. C., Conti, A., Calzoni, E., Corte, L., Santi, C., Rosati, O., Cardinali, G., & Emiliani, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073979 · Cited by 7
“It is estimated that fungal diseases affect over 1 billion individuals annually, leading to approximately 1.5 million deaths [26].”
BackgroundInfluentialFernández, N., Caceres, D. H., Serrano, J. A., et al. (2024) · Medical Mycology · doi:10.1093/mmy/myae054 · Cited by 7
Assessment of Systemic Fungal Infections among Diabetic Patients in Enugu, Nigeria
Udeani, T. K., Nneka, A., & Ezenwaka, U. (2018) · Journal of Infectious Diseases and Epidemiology · doi:10.23937/2474-3658/1510051 · Cited by 8
“Severity of these fungal infections ranges from asymptomatic-mild mucocutaneous infections to life threatening systemic infections [2].”
BackgroundNg, T. S., Looi, L. J., Ong, B. S., & Chong, P. P. (2018) · Journal of Herbmed Pharmacology · doi:10.15171/jhp.2018.36 · Cited by 8
“5 million fungal species, where Candida is among the 300 pathogenic fungal species that causes ~700 000 cases of infection, annually (1-3).”
BackgroundFungal immunology in clinical practice: Magical realism or practical reality?
Chang, C. C., & Levitz, S. M. (2019) · Medical Mycology · doi:10.1093/mmy/myy165 · Cited by 10
The Use of Whole Genome and Next-Generation Sequencing in the Diagnosis of Invasive Fungal Disease
El-Kamand, S., Papanicolaou, A., & Morton, C. O. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-00363-5 · Cited by 8
Grand Challenges in the Research of Fungal Interactions With Animals
Wang, C. (2020) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2020.602032 · Cited by 7
“For example, in addition to the invasive human diseases caused by the commensal fungi such as the species of Cryptococcus, Candida, Aspergillus, Coccidioides, and Pneumocystis genera, emerging threats have also been clinically reported from the infection of Fusarium and Mucormycetes fungi to the patients with a compro…”
BackgroundSpecies Distribution and Antifungal Susceptibility of Aspergillus Clinical Isolates in Lebanon
Osman, M., Bidon, B., Abboud, C., et al. (2021) · Future Microbiology · doi:10.2217/fmb-2020-0141 · Cited by 7
Fulgêncio, D. L. A., da Costa, R. A., Guilhelmelli, F., Silva, C. M. D. S., Ortega, D. B., de Araújo, T. F., Silva, P. S., Silva-Pereira, I., Albuquerque, P., & Barreto, C. C. (2021) · AIMS Microbiology · doi:10.3934/microbiol.2021003 · Cited by 7
Ngouana, V., Fokou, P. V. T., Menkem, E. Z., et al. (2021) · International Journal of Biological and Chemical Sciences · doi:10.4314/ijbcs.v15i2.4 · Cited by 7
“…of other health problems including surgical operations, asthma, malnutrition, AIDS, cancer, alcoholism, organ transplantation, diabetes, corticosteroid therapies and the widespread drug resistance (Nowak and Szyfter, 2008; Tudela and Denning, 2017; Bongomin et al., 2017; Ghaddar et al., 2020).”
BackgroundFormulation and Evaluation of Niosomal Gel of Antifungal Luliconazole
Mishra, S., & Gupta, R. A. (2022) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v12i6-s.5705 · Cited by 7
Hassanzad, M., Mortezaee, V., Bongomin, F., Poorabdollah, M., Sharifynia, S., Maleki, M., Hedayati, N., Velayati, A. A., & Hedayati, M. T. (2019) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2019.02.001 · Cited by 9
Self-citationSuperficial mycoses in Belgium: Burden, costs and antifungal drugs consumption
Becker, P., Lecerf, P., Claereboudt, J., Devleesschauwer, B., Packeu, A., & Hendrickx, M. (2020) · Mycoses · doi:10.1111/myc.13063 · Cited by 9
Mechanisms of Antifungal Drug Resistance
Francesconi, F., Jálkh, A. P., Lupi, O., & Khalfe, Y. (2021) · Updates in clinical dermatology · doi:10.1007/978-3-030-68321-4_8 · Cited by 8
Hain, S., & Drummond, R. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00102-6 · Cited by 8
O’Donnell, S., Rezende, G. D., Vernadet, J., Snirc, A., & Ropars, J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.03.601904 · Cited by 7
The value of calcofluor white in the diagnosis of invasive fungal diseases
Zhang, S., Chen, Z., Deng, Z., et al. (2024) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2024.116186 · Cited by 6
Novel Drug Delivery Systems for the Management of Fungal Keratitis
Ruan, M., Wang, R., & He, Y. (2024) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2023.0161 · Cited by 7
Tanka, Z. Y., Odogu, A. N., Ngouana, V., Taghu, F. L. T., Mforbesi, A. L., Nguena-Dongue, B.-N., Ndi, J. N., Kamdem, B. P., Lunga, P. K., & Boyom, F. F. (2024) · BioMed · doi:10.3390/biomed4010005 · Cited by 5
“Bongomin et al. [4] reported that patients with compromised immune function are especially prone to fungal pathogens, which account for at least 13 million infections and 1.5 million deaths in the world annually [4].”
BackgroundInfluentialBrandt, M., Cao, Z., Krishna, C., Reedy, J. L., Gu, X., Dutko, R. A., Oliver, B. A., Tusi, B. K., Park, J., Richey, L. J., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113944 · Cited by 9
Genet, A., & Girma, A. (2024) · Universa Medicina · doi:10.18051/univmed.2024.v43.102-113 · Cited by 6
“Candida auris (25, 26, 48) • Invasive candidiasis Aspergillus fumigatus (5 , 29, 34, 49) • Invasive aspergillosis ) (32, 34) • Mucormycosis o Lungs and sinuses, eye, central nervous system, and gastrointestinal tract ✓ Amphotericin B Inherently resistant to fluconazole, voriconazole and…”
BackgroundChauhan, V., Kumar, A., Tripathi, S., Jha, M., Kumar, N., Poluri, K. M., & Gupta, P. (2024) · Discover Public Health · doi:10.1186/s12982-024-00274-y · Cited by 8
“Depending upon the body part, fungal infection ranges from superficial to invasive; based on estimations of susceptible populations and incidence rates, it has been determined that invasive candidiasis results in roughly 700,000 cases per year [10].”
Hussain, A., Wang, Y. Q., Mo, E., Khan, M. N., Zhang, Q., Li, L., Zhu, J., & Zhu, M. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s495250 · Cited by 6
Antifungal Policy and Practice Across Five Countries: A Qualitative Review
Denning, D. W., Perfect, J. R., Kostova, N. M., Haderi, A., Armstrong, H., Hardenberg, M. C., Chavez, E., Altevogt, B. M., Holmes, P., & Aram, J. A. (2025) · Journal of Fungi · doi:10.3390/jof11020162 · Cited by 7
“Each year, an estimated 150 million people experience serious fungal infections, with prevalence increasing worldwide [1].”
Self-citationOduselu, G. O., AJANI, O. O., Ogunnupebi, T. A., et al. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00114e · Cited by 6
Kang, Y., Li, Q., Ma, W., Xu, C., Jia, W., & Wang, P. (2025) · Scientific Reports · doi:10.1038/s41598-025-97587-y · Cited by 9
Reemergence of zoonotic sporotrichosis in Brazil as a public health threat
Freire, C. E. C. D. A., & Reis, R. M. (2025) · Discover Public Health · doi:10.1186/s12982-025-00598-3 · Cited by 6
Stoyanova, M., Gledacheva, V., & Nikolova, S. (2025) · Applied Sciences · doi:10.3390/app15126441 · Cited by 18
Lorenzo, D. P., Rebollo, N., Sánchez‐Hernandez, J. G., Vázquez-López, L., Otero, M. J., & Castañeda, A. Z. (2025) · Life · doi:10.3390/life15060946 · Cited by 8
“Invasive fungal infections (IFIs) represent a significant challenge for clinicians, given that the number of patients susceptible to developing these infections has increased considerably in recent years, and that they are associated with a high mortality rate [1].”
García-Carnero, L. C., Li, X., de Castro, P. A., Pinzan, C. F., Campanella, J. E. M., Malavazi, I., Yoshimura, M., Isuhuaylas, L. A. V., Yashiroda, Y., Boone, C. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60991-z · Cited by 10
Therapeutic Potential of Propolis in Preclinical Models of Cancer and Infectious Diseases: A Review
Pierański, M. K., Kaniowski, D., & Szweda, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168041 · Cited by 6
“Propolis has attracted attention as a natural antifungal agent due to its broad-spectrum activity and favourable safety profile [121,122].”
Caspofungin binding to iron compromises its antifungal efficacy against Candida albicans
Pedras, A., Malta-Luís, C., Lima, L. M. P., Mil‐Homens, D., Amaral, C., Duarte, A. G., Antunes, W., Gaspar‐Cordeiro, A., Louro, R. O., Lamosa, P., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08834-x · Cited by 7
“Invasive fungal infections (IFIs), in which fungi enter the bloodstream and/ or invade internal organs 1 , are responsible for approximately 1.5 million deaths worldwide each year 2 .”
InfluentialSyed, S. M., Sowmya, T., & Koteswari, P. (2025) · Biomedical Materials & Devices · doi:10.1007/s44174-025-00557-1 · Cited by 7
Li, J., Han, Z. W., Gao, S. S., Guo, Q., & Cang, H. Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1672343 · Cited by 8
“Despite effective chemoprophylaxis, current estimates indicate up to 500,000 annual cases globally, with mortality rates ranging from 10% to 50% (41 – 43).”
Overcoming antifungal resistance in Candida albicans via RNA interference: a therapeutic perspective
Mundhe, A. K., & Rajkumari, R. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1675921 · Cited by 7
Paulin, O. K. A., Tsavou, A., Priest, E. L., Griffiths, J. S., Lortal, L., Kempf, A., Chow, E. W. L., Pang, L. M., Wickramasinghe, D. N., Lyon, C. M., et al. (2025) · mBio · doi:10.1128/mbio.03304-25 · Cited by 8
Natural Source-Derived Compounds with Antifungal Activity Against Medically Relevant Fungi
Gómez-Gaviria, M., Baruch-Martínez, D. A., & Mora-Montes, H. M. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s554647 · Cited by 9
The human mycobiome: a critical yet understudied component of health and disease
Mohammadi, R., Morovati, H., & Safari, F. (2025) · Microbiology · doi:10.1099/mic.0.001631 · Cited by 9
“Candida albicans is a prevalent fungal pathogen in humans, causing millions of symptomatic infections each year [34].”
Smart Hydrogels for Treatment of Microbial Diseases
Ünlü, B., Ropero-Vega, J. L., Alvarez-Caballero, J. M., Flórez-Castillo, J. M., & Türk, S. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18020198 · Cited by 6
“…the most prevalent opportunistic pathogens are Candida albicans , with 5142 cases of invasive candidiasis reported in the United Kingdom in 2016 [94], and Staphylococcus aureus , which causes severe skin infections in susceptible patients such as those with burns or under immunosuppression [95].”
Murtagh, M. M., White, P. L., Rodrı́guez-Tudela, J. L., Alastruey‐Izquierdo, A., Chen, S. C.-A., Dufresne, P. J., Gómez, B. L., García‐Effrón, G., Trainor, B. W., García-Vello, P., et al. (2026) · The Lancet Microbe · doi:10.1016/j.lanmic.2025.101307 · Cited by 10
Structural basis of fungal β-1,3-glucan synthase inhibition by caspofungin
Ren, Z., Chhetri, A., Liu, C., Offner, S., Sharma, K., Borgnia, M. J., Im, W., Yokoyama, K., & Lee, S. (2026) · Nature · doi:10.1038/s41586-026-10409-7 · Cited by 11
“Invasive fungal infections pose life-threatening risks to the increasing population of immunocompromised patients 1,2 .”
Borman, A. M., Fraser, M., Patterson, Z., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.10.010 · Cited by 6
Singh, S., Hans, S., Ahmad, A., Fatima, Z., & Hameed, S. (2022) · International Microbiology · doi:10.1007/s10123-022-00262-9 · Cited by 6
Li, X., Chen, S., Lyu, X., & Tian, J. (2022) · Medical Mycology · doi:10.1093/mmy/myac087 · Cited by 8
Loh, J. T., Teo, J. K. H., Kannan, S., Verma, C. S., Lim, H. H., & Lam, K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071780 · Cited by 7
Rukari, T., Pingale, P., & Upasani, C. D. (2023) · Journal of Current Science and Technology · doi:10.59796/jcst.v13n2.2023.1856 · Cited by 6
Miao, Y., Ding, T., Liu, Y., Zhou, X., & Du, J. C. (2023) · Animals · doi:10.3390/ani13203222 · Cited by 7
“C. krusei is a pathogen whose infection can cause several serious diseases in both humans and animals [28].”
BackgroundFungal antigenic variation using mosaicism and reassortment of subtelomeric genes’ repertoires
Meier, C. S., Pagni, M., Richard, S., Mühlethaler, K., Almeida, J. M. G. C. F., Nevez, G., Cushion, M. T., Calderón, E. J., & Hauser, P. M. (2023) · Nature Communications · doi:10.1038/s41467-023-42685-6 · Cited by 5
“The number of expressed alleles per patient varied greatly (2 – 108).”
Simmons, B., Rhodes, J. L., Rogers, T. R., Talento, A. F., Griffin, A., Schelenz, S., Sheehan, D., Abdolrasouli, A., Griffin, A., Bosch, T., et al. (2023) · Journal of Fungi · doi:10.3390/jof9111104 · Cited by 10
Asgaonkar, K. D., Chitre, T. S., Patil, S. M., Shevate, K. S., Sagar, A. K., Ghate, D. D., & Shah, P. A. (2024) · Recent Advances in Anti-Infective Drug Discovery · doi:10.2174/0127724344269458231124123935 · Cited by 6
A potent candicidal peptide designed based on an encrypted peptide from a proteinase inhibitor
Almeida, L. H. D. O., Ramalho, S. R., Almeida, C. V., Gutierrez, C. D. O., Sardi, J. D. C. O., Miranda, A., de Oliveira, R. A., de Rezende, S. B., Crusca, E., Franco, O. L., et al. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130583 · Cited by 7
Liao, M., Xia, X., Meng, Q., Zhu, C., Liao, B., Wang, J., Gou, L., Zhou, X., Yuan, W., Cheng, L., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16333 · Cited by 7
Chen, W.-C., Chen, I., Chen, J., Liao, T., & Chen, Y. (2024) · PeerJ · doi:10.7717/peerj.17066 · Cited by 7
“The estimated global burden of IPA was about 250,000 cases ( Bongomin et al., 2017 ) and the economic load was considerable, ranging from 25,929 to 100,730 US dollars per patient hospitalization in patients with invasive aspergillosis ( Kim, Nicolau & Kuti, 2011 ).”
BackgroundTang, Y., Li, Z., Zeng, M., Li, R., Song, H., Zhang, D., Xue, F., & Qin, Y. (2024) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.4c00193 · Cited by 6
The Ecology of Pathogenic Onygenales Fungi and the Impacts of Climate Change
Luberto, E. T., Ramsey, M. L., & Kollath, D. R. (2024) · Current Clinical Microbiology Reports · doi:10.1007/s40588-024-00223-y · Cited by 8
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with compromised immune function [39].”
InfluentialFan, C., Gu, L., Lin, J., Liu, G., Wang, Q., Zhang, L., Chi, M., Xu, Q., Zhao, G., & Li, C. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1383509 · Cited by 7
“The disease is mainly concentrated in agricultural and outdoor workers, long-term contact lens wearers, and patients with excessive use of antibiotics and glucocorticoids (Bongomin et al., 2017).”
BackgroundWong, S., Chau, P. H., Chen, H., So, S. Y.-C., Chiu, K. H., Chen, J. H.-K., Li, X., Chui, C. S. L., Yuen, K., & Cheng, V. C. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s451742 · Cited by 6
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.